Aysegul Ertugrul<sup>1</sup>, Ezgi Ulusoy Severcan<sup>1</sup>, Hakan Arslan<sup>2</sup>, Ilknur Bostanci<sup>1</sup>

# Profile of patients attending a pediatric allergic clinic during COVID-19 pandemic-related lockdown: how many children could have been approached with telemedicine?

<sup>1</sup>Department of Pediatric Allergy and Immunology, University of Health Sciences Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara, Turkey

<sup>2</sup>Department of Dermatology, University of Health Sciences Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara, Turkey

### KEY WORDS

COVID-19; allergy; telemedicine; digital healtcare.

# Corresponding author

Aysegul Ertugrul
Department of Pediatric Allergy and Immunology
University of Health Sciences Ankara Dr. Sami Ulus
Maternity and Children Training and
Research Hospital
06080, Altındağ, Ankara, Turkey
ORCID: 0000-0002-8146-3386
E-mail: aysegull.ertugrul@gmail.com

# Doi

10.23822/EurAnnACI.1764-1489.305

To the Editor,

the COVID-19 pandemic has had an unprecedented impact on healthcare systems and caused hospital overload (1). For the control of the disease and to use the limited healthcare resources appropriately, it is an urgent need to plan hospital arrangements and make appropriate triage (2). In this study, we aimed to find out which patients presented to a pediatric allergy outpatient clinic in the era of the COVID-19 pandemic during curfew. We also assessed the appropriateness of the in-person visits compared to virtual consults which is preferred for safe distancing efforts to better control the pandemic situation. This is a retrospective study researching children who were admitted to the pediatric allergy outpatient clinics

between March and June 2020 in a tertiary care children's hospital. Ethics committee for clinical research of Ankara Training and Research Hospital approved the study on November 26, 2020 - protocol code: 93471371-514.10.

The demographic features, the diagnosis of the patients, the severity and control level of their medical conditions and the suitability of cases for virtual visits were recorded from the medical files. Medical conditions of children's suitability for virtual visits or demands for face-to-face interventions were detected according to the COVID-19 Pandemic Contingency Planning for the Allergy and Immunology Clinic and are shown in **table I** (3).

A total of 563 patients (352 boys, 211 girls) visited the clinic for allergic diseases during the curfew period. The median age

Table I - List of medical conditions considered suitable for in-person medical assessment during a restriction (3).

Medical conditions	Need for face-to-face evaluation
Asthma	Uncertain diagnosis.
	Uncontrolled asthma.
	Exacerbations requiring emergency room or hospitalization in the last 3-6 months.
	Requiring $\geq 2$ oral steroid courses in the last 3-6 months.
	Requiring ≥ 1 dose escalation/addition of any daily controller medication in the last 3-6 months.
Allergic rhinitis	No prioritizing recommendation.
Immunotherapy and biologics	Patients on maintenance doses of biologics and immunotherapy
	(consider converting the patient to a prefilled syringe for potential home administration if available).
Food/drug/vaccine allergy	Acute need for reintroduction.
ç	Diagnostic uncertainty.
Anaphylaxis	Symptoms that do not immediately resolve after a single dose of epinephrine.
• •	Symptoms with recurrence.
Allergic skin disorders	Severe cases of angioedema (such as pharyngeal/laryngeal, abdominal, or genital involvement).
	Acute episodes of known hereditary angioedema.
	Severe atopic dermatitis (defined according to SCORAD score).
	Atopic dermatitis with super-infection.

(interquartile range) of the patients was 76 months (21-131). The most common presentations were asthma and allergic rhinitis. Of a total of 176 patients with asthma, 66% had mild, 31.8% had moderate and 2.2% had severe asthma. Overall disease control, evaluated by using the Global Initiative for Asthma (GINA) 2020 assessment, was good, with only 5.1% of the patients' asthma being uncontrolled. Of all patients, 56 (9.9%) needed face-to-face interventions. 79 patients (14%) were evaluated by phone service, and more than half were for medication refills. The details of the patients' hospital admission and examination are shown in **table II**.

Of the patients who were determined as unsuitable for virtual visits, 26.7% had asthma, 46.4% had an active skin disorder (severe angioedema, severe atopic dermatitis, atopic dermatitis with superinfection, vasculitis), 14.2% had a food allergy (service adjustment for introduction/reintroduction of food/ formula that is a critical nutritional need), 25% were treated with subcutaneous allergen immunotherapy, and 1.8% were treated with biologicals. Our results suggest that most of the patients had non-urgent health problems, and most of them were appropriate for virtual healthcare visits. In recent publications, the majority of the outpatient visits during the pandemic were non-emergent as ours (4-6). The most common reason for healthcare attendance in the current study was asthma, followed by allergic rhinitis. High asthma severity risk or uncertain diagnosis and needs of service adjustment for subcutaneous allergen immunotherapy (SCIT) or biologics are the most noticeable medical conditions that need to be evaluated face-to-face. However, most of the asthma patients presenting were well-controlled, and the visits could be postponed. There is no need to prioritize the evaluation of patients with allergic rhinitis for face-to-face visits, except for ongoing SCIT (3). The inappropriate use of medical services points out that the elective hospital applications and appointments created by patients, as in the routine process, may not be appropriate for pandemic control. Telemedicine, smartphones and apps allow patients to get medical services in a safe way (7). Telephone tri-

**Table II** - The details of the patients' hospital admission and examination.

	Number of patients (%)
	n = 563
Patient	
Inpatient	30 (5.3)
Outpatient	454 (80.6)
Phone service	79 (14)
Living place	
Ankara (province where the hospital is located)	532 (94.5)
Out of Ankara	32 (5.5)
Number of hospital visits	
0 (only phone call, no hospital visit)	79 (14)
1	390 (69.3)
2	67 (11.9)
3	20 (3.6)
> 3	7 (1.3)

Number of patients (%)   n = 563		
The diseases of patients  Asthma  Well controlled  Partially controlled  Uncontrolled  Uncontrolled  Allergic rhinitis  Dermatitis*  128 (22.7)  Food allergy  60 (10.6)  Urticaria-angioedema  Non-allergic cutaneous conditions**  27 (4.7)  Drug allergy  16 (2.8)  Anaphylaxis  Chronic cough and/or LRTI***  15 (2.6)  Immune deficiency  9 (1.5)  Mastocytosis  4 (0.7)  Venom allergy  3 (0.5)  Other miscellaneous  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test  Performed  Not performed  You (1.2)  Potentially exposed to Coronavirus  Potentially exposed to Coronavirus  Presenting with one of potential COVID-19 symptoms  Cough, fever, sore throat  Exanthem  Needs face-to-face intervention  So (9.9)		
The diseases of patients  Asthma  Well controlled  Partially controlled  Uncontrolled  Uncontrolled  Allergic rhinitis  Dermatitis*  128 (22.7)  Food allergy  60 (10.6)  Urticaria-angioedema  Non-allergic cutaneous conditions**  27 (4.7)  Drug allergy  16 (2.8)  Anaphylaxis  Chronic cough and/or LRTI***  15 (2.6)  Immune deficiency  Mastocytosis  Venom allergy  3 (0.5)  Other miscellaneous  Noed for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test  Performed  Not performed  Not performed  You have been a symptoms  Potentially exposed to Coronavirus  Potentially exposed to Coronavirus  Presenting with one of potential COVID-19 symptoms  Cough, fever, sore throat  Exanthem  Needs face-to-face intervention  56 (9.9)		-
Asthma       176 (31.2)         Well controlled       149 (85)         Partially controlled       18 (10)         Uncontrolled       9 (5)         Allergic rhinitis       149 (26.4)         Dermatitis*       128 (22.7)         Food allergy       60 (10.6)         Urticaria-angioedema       30 (5.3)         Non-allergic cutaneous conditions**       27 (4.7)         Drug allergy       16 (2.8)         Anaphylaxis       16 (2.8)         Chronic cough and/or LRTI***       15 (2.6)         Immune deficiency       9 (1.5)         Mastocytosis       4 (0.7)         Venom allergy       3 (0.5)         Other miscellaneous       7 (1.2)         Need for examination by laboratory tests of body       102 (18.1)         fluid (blood, urine)       102 (18.1)         Performed       99 (17.6)         Not performed       464 (82.4)         Treatment with allergen immunotherapy/       15 (2.7)         biological agents       10 (1.8)         Presenting with one of potential COVID-19 symptoms       23 (4.1)         Cough, fever, sore throat       23 (4.1)         Exanthem       151(26.8)         Suitability for telemedicine       5		n = 563
Well controlled Partially controlled Uncontrolled Uncontrolled 9 (5) Allergic rhinitis 149 (26.4) Dermatitis* 128 (22.7) Food allergy 60 (10.6) Urticaria-angioedema 30 (5.3) Non-allergic cutaneous conditions** 27 (4.7) Drug allergy 16 (2.8) Anaphylaxis 16 (2.8) Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency 9 (1.5) Mastocytosis 4 (0.7) Venom allergy 3 (0.5) Other miscellaneous 7 (1.2) Need for examination by laboratory tests of body fluid (blood, urine) Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4) Treatment with allergen immunotherapy/ biological agents Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem 151 (26.8) Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	The diseases of patients	
Partially controlled Uncontrolled Uncontrolled 9 (5)  Allergic rhinitis 149 (26.4) Dermatitis* 128 (22.7) Food allergy 60 (10.6) Urticaria-angioedema 30 (5.3) Non-allergic cutaneous conditions** 27 (4.7) Drug allergy 16 (2.8) Anaphylaxis 16 (2.8) Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency 9 (1.5) Mastocytosis 4 (0.7) Venom allergy 3 (0.5) Other miscellaneous 7 (1.2)  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem 151 (26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Asthma	176 (31.2)
Uncontrolled Allergic rhinitis 149 (26.4) Dermatitis* 128 (22.7) Food allergy 60 (10.6) Urticaria-angioedema 30 (5.3) Non-allergic cutaneous conditions** 27 (4.7) Drug allergy 16 (2.8) Anaphylaxis 16 (2.8) Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency 9 (1.5) Mastocytosis 4 (0.7) Venom allergy 3 (0.5) Other miscellaneous 7 (1.2)  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem 151 (26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Well controlled	149 (85)
Allergic rhinitis Dermatitis* 128 (22.7) Food allergy 60 (10.6) Urticaria-angioedema 30 (5.3) Non-allergic cutaneous conditions** 27 (4.7) Drug allergy 16 (2.8) Anaphylaxis 16 (2.8) Chronic cough and/or LRTI** 15 (2.6) Immune deficiency 9 (1.5) Mastocytosis 4 (0.7) Venom allergy 3 (0.5) Other miscellaneous 7 (1.2) Need for examination by laboratory tests of body fluid (blood, urine) Performation of skin prick test/intradermal test Performed Not performed 99 (17.6) Not performed 464 (82.4) Treatment with allergen immunotherapy/ biological agents Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem 151 (26.8) Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Partially controlled	18 (10)
Dermatitis* 128 (22.7) Food allergy 60 (10.6) Urticaria-angioedema 30 (5.3) Non-allergic cutaneous conditions** 27 (4.7) Drug allergy 16 (2.8) Anaphylaxis 16 (2.8) Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency 9 (1.5) Mastocytosis 4 (0.7) Venom allergy 3 (0.5) Other miscellaneous 7 (1.2)  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151 (26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Uncontrolled	9 (5)
Food allergy Urticaria-angioedema Non-allergic cutaneous conditions** 27 (4.7) Drug allergy Anaphylaxis Chronic cough and/or LRTI*** Inmune deficiency Mastocytosis Venom allergy Other miscellaneous Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Not performed Not performed Formation with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem Suitability for telemedicine Needs face-to-face intervention  60 (10.6) 10 (10.8) 16 (2.8) 16 (2.8) 15 (2.6) 15 (2.6) 15 (2.7) 15 (2.7) 15 (2.7) 16 (1.8) 17 (2.7) 18 (2.8) 19 (1.5) 20 (1.8) 21 (2.8) 22 (4.1) 23 (4.1) 24 (2.8) 25 (2.7) 26 (9.9)	Allergic rhinitis	149 (26.4)
Urticaria-angioedema Non-allergic cutaneous conditions**  Non-allergic cutaneous conditions**  Drug allergy Anaphylaxis 16 (2.8) Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency Mastocytosis 4 (0.7) Venom allergy 3 (0.5) Other miscellaneous 7 (1.2)  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem 151 (26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Dermatitis*	128 (22.7)
Non-allergic cutaneous conditions**  Drug allergy Anaphylaxis Chronic cough and/or LRTI*** Inmune deficiency Mastocytosis Venom allergy Other miscellaneous  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Not performed Not performed Fotentially exposed to Coronavirus  Potentially exposed to Coronavirus  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem  Suitability for telemedicine Needs face-to-face intervention  16 (2.8) 16 (2.8) 16 (2.8) 15 (2.6) 15 (2.6) 15 (2.7) 15 (2.7) 15 (2.7) 16 (2.8) 17 (2.8) 18 (2.8) 19 (1.8) 19 (1.8) 19 (2.8) 20 (4.1) 21 (2.8) 22 (4.1) 23 (4.1) 24 (2.8) 25 (2.9)	Food allergy	60 (10.6)
Drug allergy Anaphylaxis Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency Mastocytosis Venom allergy Other miscellaneous 7 (1.2) Need for examination by laboratory tests of body fluid (blood, urine) Performation of skin prick test/intradermal test Performed Not performed Not performed Treatment with allergen immunotherapy/ biological agents Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem Suitability for telemedicine Needs face-to-face intervention 15 (2.8) 15 (2.6) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 16 (2.8) 10 (1.5) 10 (1.5) 11 (2.6) 12 (1.5) 13 (4.1) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.6) 15 (2.7) 15	Urticaria-angioedema	30 (5.3)
Anaphylaxis Chronic cough and/or LRTI*** 15 (2.6) Immune deficiency Mastocytosis 4 (0.7) Venom allergy Other miscellaneous 7 (1.2)  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Not performed Not performed 464 (82.4)  Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Non-allergic cutaneous conditions**	27 (4.7)
Chronic cough and/or LRTI***  Inmune deficiency  Mastocytosis  Venom allergy Other miscellaneous  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Not performed Not performed  Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem  Suitability for telemedicine Needs face-to-face intervention  15 (2.6)  99 (1.5)  102 (18.1)  102 (18.1)  103 (4.1)  104 (82.4)  105 (2.7)  105 (2.7)  106 (2.7)  107 (2.8)  108 (2.8)  109 (2.8)	Drug allergy	. ,
Immune deficiency Mastocytosis Venom allergy Other miscellaneous  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Performed Not performed  Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem Suitability for telemedicine Needs face-to-face intervention  9 (1.5) 4 (0.7) 9 (12.8) 102 (18.1) 102 (18.1) 103 (18.1) 104 (82.4) 15 (2.7) 15 (2.7) 15 (2.7) 15 (2.7) 15 (2.8)		16 (2.8)
Mastocytosis Venom allergy Other miscellaneous Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Not performed Not performed Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem Suitability for telemedicine Needs face-to-face intervention  4 (0.7) 3 (0.5) 4 (0.7)		. ,
Venom allergy Other miscellaneous Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed Not performed Not performed Treatment with allergen immunotherapy/ biological agents  Potentially exposed to Coronavirus  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem Suitability for telemedicine Needs face-to-face intervention  3 (0.5) 7 (1.2) 102 (18.1) 118 (464 (82.4) 15 (2.7) 15 (2.7) 15 (2.7) 15 (2.7) 15 (2.7) 15 (2.7) 15 (2.8) 15 (2.8) 15 (2.8) 15 (2.8) 15 (2.8)	Immune deficiency	. ,
Other miscellaneous 7 (1.2)  Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/ 15 (2.7) biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	•	
Need for examination by laboratory tests of body fluid (blood, urine)  Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/ 15 (2.7) biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)		. ,
fluid (blood, urine)  Performation of skin prick test/intradermal test Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Other miscellaneous	7 (1.2)
Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)		102 (18.1)
Performed 99 (17.6) Not performed 464 (82.4)  Treatment with allergen immunotherapy/biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Performation of skin prick test/intradermal test	
Not performed 464 (82.4)  Treatment with allergen immunotherapy/biological agents  Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)		99 (17.6)
Treatment with allergen immunotherapy/biological agents  Potentially exposed to Coronavirus  Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem  Suitability for telemedicine Needs face-to-face intervention  15 (2.7)  10 (1.8)  23 (4.1)  151(26.8)		, ,
Potentially exposed to Coronavirus 10 (1.8)  Presenting with one of potential COVID-19 symptoms  Cough, fever, sore throat 23 (4.1)  Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	•	15 (2.7)
Presenting with one of potential COVID-19 symptoms Cough, fever, sore throat Exanthem 151(26.8) Suitability for telemedicine Needs face-to-face intervention 56 (9.9)		1) (2./)
Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Potentially exposed to Coronavirus	10 (1.8)
Cough, fever, sore throat 23 (4.1) Exanthem 151(26.8)  Suitability for telemedicine Needs face-to-face intervention 56 (9.9)	Presenting with one of potential COVID-19 symptoms	
Exanthem 151(26.8)  Suitability for telemedicine  Needs face-to-face intervention 56 (9.9)		23 (4.1)
Needs face-to-face intervention 56 (9.9)		151(26.8)
Needs face-to-face intervention 56 (9.9)	Suitability for telemedicine	
		56 (9.9)

<sup>\*</sup>Atopic dermatitis, allergic/irritant contact dermatitis, seborrheic dermatitis; \*\*cutaneous conditions due to infectious, metabolic, dermatological or autoimmune reasons; \*\*\*LRTI: lower respiratory tract infections.

age can prevent unnecessary contact and direct available patients to telemedicine. In conclusion, according to our clinical experience in a period of curfew and strict social isolation during the pandemic, guiding all patients with digital health technologies before outpatient clinic examination would be a useful approach to reduce contact and the burden of healthcare professionals.

# **Fundings**

None.

## Contributions

All authors contributed equally to this work.

### Conflict of interests

The authors declare that they have no conflict of interests.

# References

- 1. Ferrara P, Albano L. COVID-19 and healthcare systems: What should we do next? Public Health. 2020;185:1-2. doi: 10.1016/j. puhe.2020.05.014.
- Portnoy J, Waller M, Elliott T. Telemedicine in the Era of COVID-19. J Allergy Clin Immunol Pract. 2020;8(5):1489-91. doi: 10.1016/j.jaip.2020.03.008.
- 3. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract. 2020;8(5):1477-88.e5. doi: 10.1016/j.jaip.2020.03.012.
- Cengiz FP, Emiroglu N, Bahali AG, Dizman D, Taslidere N, Akarslan TC, et al. Which dermatology patients attend to Dermatology Outpatient Clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them? Dermatol Ther. 2020;33(4):e13470. doi: 10.1111/dth.13470.
- Altun E. The most common pediatric and adult dermatology patient complaints in a month of the COVID-19 pandemic in Turkey. Dermatol Ther. 2020;33(6):e13972. doi: 10.1111/ dth.13972.
- ACEP COVID-19 Field Guide. Facility Changes. Available at: https://www.acep.org/corona/covid-19-field-guide/work-safety/facility-changes/.
- Cervino G, Oteri G. COVID-19 Pandemic and Telephone Triage before Attending Medical Office: Problem or Opportunity? Medicina (Kaunas). 2020;56(5):250. doi: 10.3390/medicina56050250.